Drugs / Sub C gp140
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01376726 | Jul 2011 → Dec 2014 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sub C gp140 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01376726 ↗ |
| Modality | Vaccine | “HIV-1 Sub Cgp140 vaccine with MF59 adjuvant” NCT01376726 ↗ |
| Route | Intramuscular | “Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.” NCT01376726 ↗ |